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A six-year comparison of patient and technique survivals in CAPD and
RD. Comparisons of patient and technique survival were made for 120
CAPD and 139 HD patients undergoing dialysis between January 1981
and December 1986. Cox's proportional hazard regression model was
used to compare patient and technique survival, with an adjustment for
pre-treatment prognostic differences. Only the patients' first treatments
were considered. The CAPD patients were 10 years older, on the
average, than the HD patients and had more complicated conditions
(58% with 3 or more co-existing risk factors vs. 35%). Overall patient
survival between CAPD and RD did not differ (P 0.2694). However,
when adjusted for patient age, sex and other comorbid complicating
conditions, CAPD patients over the age of 66 had a significantly lower
risk of death than their HD counterparts (P C 0.05). There were no
differences in the adjusted patient survival for patients aged 30 to 66.
Four pre-treatment prognostic factors had statistically significant ad-
verse effects on patient survival: age, diabetes, malignancy and periph-
eral vascular disease. Survival of the HD technique, when unadjusted,
was better than survival of CAPD (P = 0.0457). Even after adjustment
for sex and age, this difference was still very nearly significant (P =
0.0656). No risk factors were found to be significantly associated with
technique survival. Based on patient and technique survival, CAPD
would appear to be an excellent alternative to HD and may be the
preferred treatment for high risk patients over the age of 66.
In the short term, continuous ambulatory peritoneal dialysis
(CAPD) has proven to be an effective alternative to hemodial-
ysis (HD) for treatment of patients with end-stage renal disease.
However, there is still considerable debate about whether
CAPD is a valid, long-term alternative to HD, particularly in
terms of patient and technique survival [1—141. In this paper, we
present the results of comparisons of patient and technique
survivals obtained in a single institution over a six year period.
CAPD and HD survival curves were compared by life table
analysis and the proportional hazards regression model of Cox
[15, 161. The hazards regression model allows one to correct for
pre-treatment prognostic differences. The results of our analy-
sis suggest that CAPD performed as well as or better than HD
in the time period studied.
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Methods
Patient population
Between January 1981 and the end of December 1986 a total
of 259 patients at our center began treatment for end-stage renal
disease with either CAPD or HD, 120 (46.3%) on CAPD and 139
(53.7%) on HD. HD patients were dialyzed three times a week
for four hours with 1 m2 surface area dialyzers, 280 to 300
ml/min blood flow, and 500 ml/min dialysate flow. HD tech-
nique has improved during the six years of follow-up. Now all
our patients have a whole body urea clearance normalized to
total body water (Kt/vol) [17] of at least 1.0, and about 50% of
them are on bicarbonate dialysis. About 75% of our CAPD
patients perform four two-liter exchanges and about 25% three
two-liter exchanges per day. Use of the more hypertonic
dialysate bags is limited, thanks to careful diets. All patients
employ a Y-shaped connector filled, between exchanges, with a
disinfectant (Y-system) to prevent peritonitis [18].
We excluded from the study population an additional 58
patients (25 CAPD and 33 HD patients) who began treatment
between July 1979 and December 1980. Results for these
patients have been reported previously [191. Our reasons for
excluding these patients are twofold. First, we had a consider-
ably shorter experience with the CAPD program, which began
in July 1979. Secondly, patients who began CAPD after Decem-
ber 1980 had a significantly lower peritonitis rate (1 episode/22.9
patient-months) than those patients who begans CAPD prior to
1981 (1 episode/9.0 patient-months, P < 0.0001). This difference
coincided with the use of the Y-system and may explain the
reported sharp reduction in CAPD mortality from 1981 onward
[19].
Data collection
The medical history of each patient was reviewed and the
information separated into baseline and follow-up data. Base-
line information included patient code, sex, age at entry,
primary diagnosis of end-stage renal disease, the presence or
absence of pre-treatment comorbid risk factors, the patient's
first treatment modality and corresponding start date. Fol-
low-up data included the date when the first type of treatment
was stopped, the reason for ending it, the date and cause of
death and the number of peritonitis episodes for those patients
on CAPD. Follow-up information was collected through De-
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Table 1. Patient characteristics
CAPD HD Total
N=120 N=139 N=259
Age (mean SD) 58.8 15.0 48.5 17.7 53.2 17.3
Sex:
Males 66 (55%) 97 (70%) 163 (63%)
Females 54 (45%) 42 (30%) 96 (37%)
Primary renal disease
Glomerulonephritis 11(9%) 26 (19%) 37 (14%)
Diabetes 20 (17%) 4 (3%) 24 (9%)
Interstitial nephritis 10 (8%) 17 (12%) 27 (10%)
Polycystic kidney 9 (7%) 14 (10%) 23 (9%)
disease
Etiology uncertain 46 (38%) 54 (39%) 100 (19%)
Other disease 24 (20%) 24 (17%) 48 (39%)
Pre-treatment risk factors
Peripheral vascular 28 (23%) 18 (13%) 46 (18%)
disease
Cerebral vascular 21(17%) 6 (4%) 27 (10%)
disease
Ischemic 22 (18%) 17 (12%) 39 (15%)
cardiopathy
Cardiac arrhythmia 15 (13%) 5 (4%) 20 (8%)
Hypertension 91(76%) 113 (81%) 204 (79%)
Malignant 2 (2%) 0 (0%) 2 (1%)
hypertension
Diabetes 28 (23%) 13 (9%) 41(16%)
Dislipidemia 42 (35%) 56 (40%) 98 (38%)
Chronic respiratory 18 (15%) 15 (11%) 33 (13%)
infections
Tuberculosis 8 (7%) 8 (6%) 16 (6%)
Diverticulosis 15 (13%) 2 (1%) 17 (7%)
Multi-system 10 (8%) 10 (7%) 20 (8%)
diseases
Cirrhosis 10 (8%) 11(8%) 21(8%)
Urinary tract 12 (10%) 19 (14%) 31(12%)
infections
Malignancy 7 (6%) 9 (6%) 16 (6%)
No risk factors 5 (4%) 6 (4%) 11(4%)
(control)
cember 31, 1986. Only the patient's first type of treatment was
considered in the analysis.
Statistical methods
To take into account differences in sex, age and pre-treatment
risk factors, we compared patient and technique survival for
CAPD and HD by the proportional hazards regression model
developed by Cox [15, 16]. The model is described by
h(t;z) = ho(t) exp[zD]
in which h(t;z) is the hazard (death) rate of a patient having
characteristics defined by a set of covariates z; 3 is a set of
corresponding regression coefficients to be estimated, and ho(t)
is the baseline hazard rate defined for a patient having a set of
covariates z = 0. The basic assumption of this model is that the
ratio of hazard rates (that is, relative risk) for two patients with
different values of z is constant over time. This assumption was
tested by a technique described by Harrell and Lee [20]. All
variables except diabetes satisfied the proportional hazards
assumption. Consequently, the data were stratified as diabetics
and non-diabetics and risk analysis was performed after pooling
across the stratum.
Table 2. Number of risk factors per patient
Risk factors/patient CAPD HD
0 5 (4%) 6 (4%)
1 21(18%) 35 (25%)
2 25 (2 1%) 50 (36%)
3 69 (58%) 48 (35%)
Total 120 (100%) 139 (100%)
Mean SD 3.0 1.7 2.3 1.4
In analyzing patient survival, dropouts due to transplanta-
tion, return of kidney function, transfer to other centers and
failure of treatment were all considered as lost to follow-up.
However, in order to avoid attributing to the second treatment
fatuities due to the first treatment, all deaths that occurred in
the first two months after switching methods and reasonably
referable to the previous treatment (for example, deaths from
infections or cachexia after a transfer from CAPD to HD) were
included as deaths on first treatment.
Technique survival includes only method failures, with all
other outcomes treated as lost to follow-up, including death. In
particular, only those patients whose treatment modality was
changed (for example, from CAPD to HD or from HD to CAPD
or hemofiltration) were classified as having a technique failure.
Patients whose kidney function returned, who had a transplant,
who moved to another center while on the same treatment, or
who died were all treated as lost to follow-up.
We began our analysis by comparing the overall effects of
CAPD and HD on patient and technique survival by life table
methods [16]. Next, we used the Cox proportional hazards
regression model to evaluate the effects of sex, age, modality,
age x modality and pretreatment risk factors (Table 1). To
better identify those risk factors associated with patient and
technique survival, we used a stepwise procedure to select only
those risk factors that significantly affect survival. This was
done with diabetes as a blocking variable and with sex, age,
modality and age x modality effects being retained in the model
at all times. The results of the stepwise procedure agreed
closely with the results obtained with the model incorporating
all risk factors. The regression coefficients and their P values
associated with sex, age, modality and age x modality re-
mained virtually unchanged when the set of pre-treatment risk
factors included in the model were reduced from those listed in
Table 1 to those found significant by the stepwise procedure.
Consequently, we have elected to report only those results
obtained by the stepwise procedure.
Results
Patient characteristics
A summary of patient characteristics is presented in Table 1.
The CAPD patients were 10 years older, on the average, than
the HD patients. Over twice as many CAPD patients were older
than 70 (28% vs. 11%). The ratio of male to female HD patients
was nearly twice that for CAPD patients. The majority of
patients studied had more than one risk factor present prior to
treatment therapy. Table 2 lists the patients according to the
number of pre-treatment risk factors per patient. CAPD pa-
tients had significantly more complicating conditions, with 58%
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Table 3. Number of patients by modality and reasons for drop-out
First treatment modality
CAPD Hemodialysis
Number of Number of
patients Percent patients Percent
Reasons for drop-out
Death 27 22.5 17 12.5
Recovery of renal 8 6.6 1 0,7
function
Transplantation 5 4.1 25 17.9
Transferred 0 0 36 25.8
Method failure
Inadequate vascular — — 1 0.7
access
Catheter related 2 1.6 — —
complications
Medical reasons 1 0.8 3 2,1
other than
peritonitis
Peritonitis 6 5 — —
Poor blood 2 1.6 — —
purification!
ultrafiltration
Patient/family 2 1.6 — —
choice
Still on first treatment 67 55.8 56 40.2
Overall 120 100.0 139 100.0
having three or more co-existing risk factors versus only 35%
among HD patients (P < 0.0001). CAPD patients averaged
slightly less than one more risk factor per patient (Table 2).
Results for patient survival
Table 3 summarizes patient outcomes. All the CAPD patients
have been followed by our center. Thirty-six stable HD patients
were transferred without any clinical selection to the peripheral
centers closer to their homes (according to our Regional Health
policy).
A total of 27 CAPD patients (27%) and 17 (12%) HD patients
died on their first treatment modality. Survival estimates were
computed by treating all other outcomes as lost to follow-up.
The causes of death are summarized in Table 4. Figure 1
presents the CAPD and HD patient survival curves unadjusted
for any pre-treatment prognostic differences. The 5-year CAPD
survival rate of 46% was not significantly different from the 66%
HD survival rate (P = 0.2694, Table 5).
It can be seen from Table 1 that CAPD and HD patients differ
substantially with respect to pre-treatment prognostic factors.
In general, we found that the CAPD patients were older and
sicker than the patients treated by HD. To correct for these
prognostic differences, we compared CAPD and HD patient
survival after adjusting for sex, age and pre-treatment risk
factors by Cox's proportional hazards regression model. Initial-
ly, we treated sex (0 = male, 1 female), age (expressed as a
deviation from the average of 53.2), modality (0 = HD, 1 =
CAPD), age x modality and all risk factors (0 risk absent, 1 =
present) as covariates in the model, The interaction term, age X
modality, reflects changes in the risk of death of CAPD patients
compared to HD patients when there are differences in age.
Such an effect has been observed in previous studies. Taken
collectively, these covariates had a statistically significant im-
Table 4. Number of deaths by modality and cause
First treatment modality
CAPD Hemodialysis
Number of Number of
Cause of death patients Percent patients Percent
Unknown 0 0 1 5.8
Bone marrow 0 0 1 5.8
depression
Cachexia 3 11.1 0 0
Cardiac
Cardiac arrest, cause 1 3.7 4 23.5
unknown
Fluid overload — 1 5.8
Hypertensive cardiac 1 3.7 — —
failure
Myocardial infarction 6 22.2 2 11.7
Dementia 3 11.1 1 5.8
Infection
Pulmonary 1 3.7 — —
Septicaemia 2 7.4 2 11.7
Tuberculosis, lung 1 3.7 — —
Malignant disease 6 22.2 2 11.7
Vascular
Cerebro-vascular 3 11.1 1 5.8
accident
Gastrointestinal — — 1 5.8
haemorrhage
Other identified cause — — 1 5.8
of death
Overall 27 100.0 17 100.0
Table 5. Life table estimates of patient survival
No. of
Interval years No. of Lost toa patients Percent
on treatment deaths follow-up remaining survival
CAPD 0 0 0 120 100
<1 11 28 81 89
1—2 6 28 47 81
2—3 4 13 30 73
3—4 3 13 14 64
4—5 3 4 7 46
HD 0 0 0 139 100
<1 8 58 73 92
1—2 3 28 42 88
2—3 3 15 24 80
3—4 2 8 14 72
4—5 1 10 3 66
All values determined through the end of the interval. Logrank test: P
value 0.2694.
a Lost to follow-up includes patients given transplants, recovering
renal function, moved, changing therapy; it also includes those patients
that have not completed that interval year on treatment.
pact on patient survival (P < 0.0001). Individually, sex and
modality had no significant effect on survival (P > 0.50), but
both age (P < 0.01) and age x modality (P < 0.07) did. The
regression coefficient for diabetes (0 = nondiabetic, I diabet-
ic) was not significantly different from 0, indicating no differ-
ence between diabetics and nondiabetics (P > 0.20). However,
the ratio of hazard (death) rates for diabetics and nondiabetics
was found to be in violation of the proportional hazard assump-
tion. This was the only covariate found to violate the model
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Table 6. Summary of anaylsis of risk factors for patient survival
Beta Standard Relative risk
Risk factor Value of z coefficient error P value exp(beta x z)
Sex
Female 1 —0.4268 0.3465 0.2181 0.65
Male 0 1.00
Age (Age — 53.2) 0.1290 0.0355 0.0003 1.14
Modality
CAPD 1 0.2961 0.5712 0.6041 1.34
HD 0 1.00
Age x modality
CAPD (Age — 53.2) x 1 —0.0759 0.0418 0.0694 0.93
HD (Age — 53.2) x 0 1.00
Malignancy
Present 1 1.8065 0.4318 0.0001 6.09
Absent 0 1.00
PVD
Present 1 0.7914 0.3473 0.0227 2.21
Absent 0 1.00
assumptions. Consequently, we stratified the data according to
diabetic and nondiabetic patients and compared their survival
curves by a life table analysis which takes into account all
remaining covariates. The results of this analysis showed a
significant difference in patient survival between diabetic and
nondiabetic patients, with diabetics having a higher risk of
death (P < 0.001).
Next, we performed a stepwise selection procedure, using
Cox's regression model, to determine which risk factors other
than diabetes significantly affect patient survival. This was done
for the effects of sex, age, modality and age x modality. The
difference between diabetics and nondiabetics was taken into
account by incorporating diabetes as a blocking or stratifying
variable in the model. Estimates of the regression coefficients
associated with each risk factor were pooled across diabetics
and nondiabetics, and the stepwise procedure used to select
only those risk factors significantly associated with patient
survival.
Results of the stepwise regression analysis are summarized in
Table 6. Malignancy and peripheral vascular disease (PVD)
were the only prognostic risk factors other than diabetes found
to be significantly associated with patient survival. In Table 6,
the relative risk of death is defined as the risk of death for
patients with a certain characteristic divided by the risk of death
for those without that characteristic. For example, a relative
risk of 2.21 associated with PVD means that patients with PVD
had approximately twice the risk of dying for patients without
PVD. For age, relative risks are expressed in terms of devia-
tions from the combined average age of 53.2. Thus a patient
aged 54.2 has a risk of death 1.14 times the risk of death for
patients aged 53.2. Survival curves adjusted for pre-treatment
prognostic differences are shown in Figure 2. These curves
would be for patients aged 53.2 without malignancy or periph-
eral vascular disease. The effect of diabetes is clearly demon-
strated, but among diabetics and non-diabetics, there was no
significant difference in survival in the two modalities.
We found that the effect of treatment on patient survival
changes with age. This interaction has also been observed in
other studies [1, 21, 22]. In our study of patients aged 30 to 66,
there was no significant difference in survival between CAPD
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Fig. 1. Estimatedpatient survival unadjusted for risk factors. Symbols
are (ED) CAPD; (•) hemodialysis; P = NS.
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Fig. 2. Estimated patient survival after adjusting for risk factors.
Symbols are: nondiabetics on (E) CAPD and (•) HD; diabetics on() CAPD and () HD; P = NS.
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and HD patients (P> 0.05). However, for patients aged 67 and
over, CAPD patients had a significantly lower risk of death (P <
0.05). This interactive effect is illustrated in Figure 3. The 95%
upper confidence limit for relative risk falls below a relative risk
of death for CAPP patients aged 67 and over. The larger
confidence limits between the ages of 50 and 55 reflect smaller
sample sizes with respect to the number of deaths at these ages.
Results for technique survival
Thirteen CAPD patients were shifted to HD, whereas only
four patients left HD (2 switched to CAPD, 2 to hemofiltration).
The reasons for changing methods are listed in Table 3. The
CAPD and HD technique survival curves, unadjusted for pre-
treatment prognostic differences are illustrated in Figure 4.
Corresponding one to five year survival rates are given in Table
7. In the unadjusted comparison, CAPD technique survival was
significantly lower than that of HD (P 'C 0.05).
When death was included as a technique failure, the overall
CAPD technique survival was again found to be significantly
lower than that of HD (P C 0.05). This result is not surprising,
since overall CAPD patient survival was not significantly dif-
ferent from HD patient survival. Including death as a technique
failure will, however, affect an analysis of risk factors. To
identify any potential risk factors associated only with a change
in modality, one must treat death as a loss to follow-up in order
to avoid any confounding causal effects. Consequently, in all
subsequent analyses of technique survival, death was treated as
a loss to follow-up.
To be consistent with patient survival, we continued to treat
diabetes as a blocking variable, despite the fact that there was
no significant difference in technique survival between diabetics
and non-diabetics (P> 0.20).
Stepwise regression analysis of all factors was then per-
formed to check for sex and age. However, no risk factors were
detected as being significantly associated with technique sur-
vival. Since no risk factors, including diabetes, were significant,
our final regression model incorporated sex, age, modality and
age x modality as the only covariates. The combined effect of
these covariates was not statistically significant (P > 0.20).
Individually, there was no significant effect of sex, age and age
x modality (Table 8). After adjustment for sex and age differ-
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Table 7. Life table estimates for technique survival
Interval Patients No. of
years on changing Lost to" patients Percent
treatment therapy follow-up remaining survival
CAPD 0
<1
1—2
2—3
3—4
4—5
0
2
6
2
3
0
0
37
28
15
13
7
120
81
47
30
14
7
100
98
89
84
71
71
HD 0
ci
1—2
2—3
3—4
4—5
0
4
0
0
0
0
0
62
31
18
10
11
139
73
42
24
14
3
100
96
96
96
96
96
Patient age at entry
Fig. 3. Relative risk of death of patients on CAPD compared to
hemodialysis at any given age. Symbol is: 0 95% confidence limits.
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All values determined through the end of the interval. Logrank test: P
value 0.0457.
"Lost to follow-up includes patients given transplants, recovering
renal function, moved or dead; it also includes those patients that have
not completed that interval year on treatment.
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Fig. 4. Estimated technique survival unadjusted for risk factors. Sym-
bols are (0) CAPD; (U) HD. 0 12 24 36 48 60
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FIg. 5. Estimated technique survival after adjusting for sex and age.
Symbols are: (0) CAPD; (U) HD.
Majorca et a!: CAPD and HD patient survival 523
Table 8. Summary of analysis of risk factors for technique survival
Risk factor Value of z
Beta
coefficient
Standard
error P value
Relative risk
exp beta
Sex
Female
Male
Age
Modality
CAPD
HD
Age x modality
CAPD
HD
1
0
(Age — 53.2)
1
0
(Age — 53.2) X 1
(Age — 53.2) x 0
—0.1187
0.0326
1.0579
—0.0365
0.4985
0.0376
0.5845
0.0420
0.8118
0.3871
0.0656
0.3856
0.89
1.00
1.03
2.93
1.00
0.96
1.00
ences, survival of CAPD was found not to be significantly
different from survival of HD (relative risk of method failure
was 2.93, P = 0.0656). The fact that no variables were signifi-
cant may be due to the relatively small number of technique
failures (13 CAPD vs. 4 HD) and hence to an inability to detect
any differences that might exist.
Discussion
Use of CAPD, although extensively and impressively wide-
spread, is not yet homogeneous or ubiquitous, because many
nephrologists still consider the method unreliable for long-term
treatment. Reasons for mistrust are frequency of peritonitis,
claims of peritoneal ultrafiltration and loss of peritoneal clear-
ance over time, and referred cases of sclerosing encapsulating
peritonitis with poor prognosis.
As a matter of fact, much progress has been made in CAPD
treatment in the last few years and, today, nephrologists with
large experience with both HD and CAPD actually wonder
whether there is any difference between the two methods in
long-term patient survival.
The best way to overcome unjustified resistance to more
extensive use of CAPD would be a prospective, controlled
study comparing CAPD and HD results. Unfortunately, such a
study is practically impossible for logical and ethical reasons.
Basically, patient acceptance of a dialysis method varies with
age and familial or social conditions. Young people frequently
refuse CAPD for aesthetic reasons (the fear that abdominal
catheter will have a negative impact on partner psychology and
sexuality) and because they think that diurnal bag exchange
could hamper full working activity. On the contrary, older
people mostly appreciate the feasibility of home treatment, the
possibility to do it without involvement of a partner, the
freedom from any dialysis machine, with the liberty of travel-
ing. The time involved is not a problem, since they are usually
retired or have part-time jobs.
These and other reasons make it impossible to randomly
assign patients to groups. Staff conviction that one method or
another is preferential under certain conditions (for example,
diabetics or old patients with cardiovascular instability do
better on CAPD) leads to a veritable pretreatment selection,
due both to patient preference and staff beliefs. All these factors
also influenced the composition of the groups in this paper, as
can be easily assessed from the patients' characteristics shown
in Table 1.
The heterogeneity of CAPD and HD populations increases
the difficulty of comparing patient survival for the two methods
and accounts for the variety of results obtained in former
studies that compare patients paired [31 or stratified according
to medical, social or demographic criteria [4, 5, 8, 10, 14]. A
statistical treatment of data that enables one to correct for
pre-treatment selection, such as Cox's proportional hazard
method, is therefore necessary.
Applying the Cox model only age, age x modality, malig-
nancy and peripheral vascular disease appeared to influence
patient survival. Our analysis failed to demonstrate any detri-
mental effects of such important risk factors as ischemic cardi-
opathy, cerebrovascular disease and others, as was found in
previous studies [1, 14]. Although the number of patients we
studied was not small (N 259) and the period of follow-up was
maximal for CAPD, the relatively small number of outcomes
(44 deaths, 17 technique failures) allows for a sizeable chance of
not detecting differences that may exist. Larger multi-center
studies with significantly more patients are needed to ensure
that differences are found. After correcting for pre-treatment
selection, survival percentages in the two methods were much
closer than before correction, especially for non-diabetics.
Also, in other studies with shorter follow-up, survivals on
CAPD and HD did not differ [1, 141. In this study the influence
of diabetes was strong but not different for both methods, and
our data do not support the idea that CAPD is a better treatment
for these patients. Since our CAPD and HD patients differed
greatly in age, the correction for age risk was particularly
important in the evaluation of differences. Patient survival was
similar for the two methods in patients aged 30 to 66 (P> 0.05),
but was better on CAPD for patients aged 67 and over (P <
0.05). This observation is particularly important in consider-
ation of the preference for CAPD of the oldest patients men-
tioned above. Causes of death were not impressively different
in the two groups. It is remarkable that no CAPD patient died
from peritonitis. Four patients died from infectious diseases not
connected with peritonitis. The higher incidences of myocardial
infarction, cerebro-vascular accidents, dementia and cachexia
are probably referable to the patients' older age. Cachexia
accounted for 11% of deaths in CAPD patients. This relatively
high incidence, also seen by others [5], may be related to the
well known reduced appetite of CAPD patients, more evident in
the oldest ones. In HD patients death from cardiac arrest was
much more frequent than in CAPD patients.
The CAPD method failure was higher than the HD failure.
This is a usual observation and was true also for our experience.
CAPD failure is due in large part to the high frequency of
peritonitis. It is overemphasized in the literature because the
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peritonitis rate is still very high in many centers. After conclud-
ing a prospective controlled trial on the use of a Y-shaped
connector filled between bag exchanges with a disinfectant [19],
we have progressively extended the use of this technique to all
patients and have progressively reduced the overall peritonitis
rate to one episode every 35 patient-months in our overall
CAPD population. That might explain our dropouts being fewer
than those reported in the literature. As regards other causes of
CAPD dropout in this study, we have so far observed only one
case of ultrafiltration loss and one case of insufficient blood
purification (together: 1.6%). No case of scierosing encapsulat-
ing peritonitis has ever been observed in our center. These
results suggest that a reasonably long duration of the perito-
neum as a dialysis membrane is possible.
In our opinion a comparison of CAPD to HD for method
failure is of limited value once sufficient control of the perito-
nitis rate has been obtained, as it is today with the use of new
devices like the one we use. One must not forget that HD has
been available for two decades longer than CAPD and that HD
results have been significantly improved by the recent use of
dialysis fluids with hypertonic sodium or bicarbonate buffer and
by hemodiafiltration. It is probable that in the next two decades
CAPD will also improve enough to compete successfully with
HD in terms of method failure.
In this study we restricted our analyses to considering only
the patient's first treatment modality. In doing so we may be
losing important information that relates changes in treatment
therapy, including transplantation, to patient survival. To do
this requires a more sophisticated study, with follow-up and
analyses such as described by Hutchinson et al [221.
Despite the limitations of our study and the fact that results
obtained in a single institution are not universally applicable,
the data suggest that CAPD provides an excellent alternative to
HD. For high risk patients over aged 67 and over, CAPD may
even be the preferred treatment.
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